For Generics Industry, Will Larger Firms Mean Weaker Lobbying?
Executive Summary
New CEO Chip Davis wants GPhA sitting at the table in policy debates rather than being on the menu, but industry consolidation means there are fewer dues-paying members to fill the chairs.
You may also be interested in...
GPhRMA? Generic Trade Group Picks Up Another Exec From Brand Association
PhRMA Senior Counsel Jeffrey Francer will become GPhA's General Counsel in mid-November.
GPhRMA? Generic Trade Group Picks Up Another Exec From Brand Association
PhRMA Senior Counsel Jeffrey Francer will become GPhA's General Counsel in mid-November.
Pricing Transparency Policies Not Suited To Generics, GPhA Argues
Legislation like FAIR drug pricing bill, which requires sponsors to justify price increases over 10%, could ultimately discourage generic competition since it could burden ANDA sponsors for even small dollar increases, GPhA CEO Davis argues.